CIBACALCIN
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIBACALCIN is an injectable small-molecule product approved by Novartis in 1986 for an undisclosed indication. The specific mechanism of action and therapeutic area remain proprietary or unavailable in current data sources.
LOE Approaching
With LOE approaching on a 1986-approved product, this brand faces decline and likely operates with a minimal, restructuring-focused team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CIBACALCIN offers limited career growth; the product is in mature decline with no linked job openings. Roles are focused on defending market share, managing generic transition, and cost optimization rather than innovation or expansion.
Brand Manager (Legacy)Sales Operations
Worked on CIBACALCIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.